This week Genzyme Corp. announced their phosphorus binding drug Renagel庐 is being replaced by the newer binder Renvela庐 in the US. The newer drug, available since March 2008, is similar to Renagel庐 but with the added benefit of a carbonate buffer. Renvela庐 contains no calcium or metals, and is not absorbed as it passes through the GI tract. It has less impact on bicarbonate levels and fewer GI side effects compared to Renagel庐.
The transition is expected to be completed by September 2009.
Genzyme is also working on a powdered form of Renvela庐, expected to be available later this year.
Phosphorus binders are medications that bind phosphorus in the gastrointestinal (GI) tract to help reduce absorption into the blood. Binders along with a low phosphorus diet help dialysis patients maintain normal phosphorus levels. Uncontrolled phosphorus can cause heart and bone problems in people with kidney disease.
